Streetbeat News

RAIN

Rain Oncology Inc

Employees

38

Industry

Medicinal and Botanical Manufacturing

rain therapeutics is a san francisco bay area-based biotechnology company, focused on developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver.

Open

1.24

Mkt cap

44M

Volume

3.7M

High

1.27

P/E Ratio

-0.58

52-wk high

11.32

Low

1.21

Div yield

N/A

52-wk low

0.82

Rain Oncology disclosed in an SEC 8K filing that it has received 15 demand letters from purported company stockholders in relation to its proposed deal with Pathos AI. The company denies all allegations made in these demand letters.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 1:08 pm

Rain Oncology Inc (NASDAQ:RAIN) is set to be acquired by Pathos AI Inc. for $1.16 per share in cash plus a contingent value right (CVR) for potential additional cash payments of up to $0.17 per share. The offer is a 17% premium over Rain's stock price as of October 13, 2023. The deal, expected to close in January 2024, follows Rain's disappointing Phase 3 MANTRA data for milademetan, which did not meet its primary endpoint. Rain went public in April 2021. RAIN shares rose 2.54% to $1.21 in premarket trading.

Portfolio Pulse from Vandana Singh

December 14, 2023 | 12:26 pm

Rain Oncology is set to be acquired by Pathos AI for $1.16 per share, plus additional contingent value rights (CVRs). The deal includes a cash CVR payment and a development CVR payment related to the drug milademetan. The tender offer is contingent on certain conditions, including a minimum share tender and available cash. Stockholders holding 44% of Rain's shares have agreed to support the tender. If successful, the transaction is expected to close in January 2024.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 6:44 am

Rain Oncology (NASDAQ:RAIN) reported Q3 losses of $(0.19) per share, beating the analyst consensus estimate of $(0.27) by 29.63%. This represents a 72.06% increase over losses of $(0.68) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:49 pm

Insiders have recently bought shares in four penny stocks: Parks! America, Inc. (OTC:PRKA), Rain Oncology Inc. (NASDAQ:RAIN), Intrusion Inc. (NASDAQ:INTZ), and Mentor Capital, Inc. (OTC:MNTR). Parks! America's revenues fell in the recent quarter, Rain Oncology posted a wider-than-expected quarterly loss, Intrusion was awarded a $5 million multi-year shield agreement, and Mentor Capital's stock gained around 38% year-to-date.

Portfolio Pulse from Lisa Levin

October 16, 2023 | 1:07 pm

Rain Oncology, Inc. (NASDAQ:RAIN) has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (CVR) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain's programs. Rain's Board of Directors will review and evaluate the proposal.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:05 pm

Several healthcare stocks experienced significant movement in Friday's after-market session. Bellerophon Therapeutics, Cingulate, Rain Oncology, Artelo Biosciences, Processa Pharma, and Eiger BioPharmaceuticals saw gains, while Eloxx Pharmaceuticals, TRACON Pharma, Universe Pharmaceuticals, Purple Biotech, RVL Pharmaceuticals, and OpGen experienced losses.

Portfolio Pulse from Benzinga Insights

October 13, 2023 | 9:31 pm

Citigroup analyst Yigal Nochomovitz has maintained a Neutral rating on Rain Oncology (NASDAQ:RAIN) and lowered the price target from $1.5 to $1.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 1:46 pm

In Monday's after-market session, several healthcare stocks saw significant movement. Bionomics (BNOX), Tempest Therapeutics (TPST), Sunshine Biopharma (SBFM), Lucy Scientific Discovery (LSDI), Societal CDMO (SCTL), and Celularity (CELU) saw their stocks rise, while Orgenesis (ORGS), SCWorx (WORX), Reshape Lifesciences (RSLS), Rain Oncology (RAIN), PaxMedica (PXMD), and TFF Pharmaceuticals (TFFP) saw their stocks fall.

Portfolio Pulse from Benzinga Insights

August 28, 2023 | 9:31 pm

Rain Oncology reported Q2 losses of $(0.61) per share, missing the analyst consensus estimate of $(0.51) by 19.61%. This is a 7.58% increase over losses of $(0.66) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.